RA Capital Management, L.P., functioning as both a substantial 10% shareholder and a board director within Artiva Biotherapeutics, Inc. (NASDAQ:ARTV), initiated the acquisition of 6,522 shares of the company's common equity on July 13, 2026. The aggregate financial value attributed to this specific transaction stands at $58,306. The execution of these purchases occurred at a weighted average price point of $8.94 per share. Individual transaction prices within this block ranged narrowly between $8.89 and $8.95. This filing serves as a corrective amendment to a Form 4 document originally submitted on July 14, 2026. The amendment was necessitated by the identification of a clerical error in the number of shares initially reported in that earlier filing.
RA Capital Management, L.P. operates as the investment manager for multiple investment vehicles. Among these is the RA Capital Healthcare Fund, L.P., which is the entity that directly holds the shares reported in this transaction. The individuals responsible for this filing, specifically Dr. Peter Kolchinsky and Mr. Rajeev Shah, have formally disclaimed beneficial ownership of these securities. Their disclaimer applies except to the extent of their pecuniary interest in the funds managed by RA Capital. Post-transaction, RA Capital Management, L.P. indirectly holds a total of 16,817,543 shares of Artiva Biotherapeutics common stock.
Market Context and ValuationArtiva Biotherapeutics stock has demonstrated notable price movement following this reported activity. The stock price has climbed to $10.13. According to data provided by InvestingPro, this price level reflects a return of 194% over the past year. Despite this upward momentum, InvestingPro analysis indicates that the stock is currently trading at a valuation that appears overvalued relative to its calculated Fair Value. However, analyst sentiment remains constructive. Analysts have established bullish price targets for the stock, with estimates ranging from $23 to $41. InvestingPro also highlights the stock's high volatility profile. Subscribers to InvestingPro have access to 11 additional exclusive tips regarding this equity.
Clinical and Corporate DevelopmentsArtiva Biotherapeutics has advanced its regulatory and clinical pipeline. The company received Regenerative Medicine Advanced Therapy designation from the FDA for its rheumatoid arthritis treatment, AlloNK, when used in combination with rituximab. This designation provides the company with access to expedited development and review processes. In parallel, Artiva presented clinical data at the European Alliance of Associations for Rheumatology Congress. The data indicated that 71% of rheumatoid arthritis patients in a Phase 2a basket trial achieved an ACR50 response after six months of follow-up.
Financial analyst coverage also reflects ongoing interest. Cantor Fitzgerald reiterated an Overweight rating for Artiva Biotherapeutics. The firm maintained a price target of $40.00. This action followed a webinar with Artiva's CEO, Fred Aslan, which focused on the company's strategic outlook and safety profile. Corporate leadership has also seen changes. Artiva announced that Diego Miralles, M.D., resigned from the board of directors. His departure allows him to assume the role of President and Head of Research and Development. This resignation reduced the total board size from eight members to seven. The company stated that the resignation was not due to any disputes.